Cutaneous adverse events of anti–programmed cell death|1 therapy ...

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)

Anti-PD-1 therapy is associated with the development of immune-related cutaneous events. Lichenoid reactions, eczema, and vitiligo are the 3 most prevalent ...

Cutaneous adverse events of anti–programmed cell death-1 therapy ...

The utilization of checkpoint inhibitors will continue to expand for both melanoma and other malignancies, and therefore, knowing what to ...

Cutaneous adverse events of anti-programmed death 1 ... - PubMed

To date, cutaneous toxicities of combination therapies of anti-programmed death-1 (anti-PD1) and ipilimumab are poorly described. Understanding cutaneous ...

Association of Cutaneous Immune-Related Adverse Events With ...

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti– ...

Cutaneous adverse events (AEs) of anti-programmed cell death (PD ...

Anti-PD-1 therapy is associated with the development of immune-related cutaneous events. Lichenoid reactions, eczema, and vitiligo are the 3 most prevalent ...

Cutaneous adverse events (AEs) of anti-programmed cell death (PD ...

Anti-PD-1 therapy is associated with the development of immune-related cutaneous events. Lichenoid reactions, eczema, and vitiligo are the 3 ...

Cutaneous immune-related adverse events in patients with ...

Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T- ...

Anti–Programmed Cell Death 1 Cutaneous Toxic Effects and ...

Cutaneous toxic effects were associated with superior clinical outcomes in advanced melanoma patients treated with anti–PD-1 therapy.

Cutaneous adverse events in patients treated with PD-1/PD-L1 ...

Immune checkpoint inhibitors (ICIs) have been introduced as breakthroughs in cancer treatment. Programmed cell death-1/programmed death-ligand 1 ...

Characterization and Prognostic Significance of Cutaneous Adverse ...

Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy. Ye Jin Lee ,1 Hak Tae Kim , ...

Cutaneous Adverse Events Associated with Immune Checkpoint ...

Lichenoid dermatitis affects nearly one-fifth of patients treated with anti-PD-1 agents, and the time to onset of lichenoid dermatologic toxicity ranges from 3 ...

Adverse Cutaneous Outbreaks by programmed cell death-1 (PD-1 ...

The anti-PD-1/PD-L1 drugs can cause numerous cases of cutaneous reactions, hence these toxicities are characterized as the most frequent immune- ...

Diverse cutaneous adverse eruptions caused by anti-programmed ...

The anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies have shown exceptional activity in ...

Adverse effects of immune-checkpoint inhibitors - Nature

Treatment with ICI combination therapy is associated with earlier-onset skin toxicities with an increased incidence and greater severity than ...

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)

Conclusion Anti-PD-1 therapy is associated with the development of immune-related cutaneous events. Lichenoid reactions, eczema, and vitiligo ...

Cutaneous immune‐related adverse events in patients with ...

Low‐grade cutaneous IrAEs are common and are usually managed supportively while continuing CPI therapy. Delayed presentations arising after established use of ...

Lichenoid reaction in a patient on antiePD-1 therapy. PD-1, programmed cell death protein 1. E. Wang et al. / Ann Allergy Asthma Immunol 126 (2021) 613e622.

Association of Cutaneous Immune-Related Adverse Events with ...

Association of Cutaneous Immune-Related Adverse Events with Increased Survival in Patients Treated with Anti-Programmed Cell Death 1 and Anti-Programmed Cell ...

Psoriasiform dermatitis has also been reported in patients with melanoma treated with PD-1/PD-L1 inhibitors. Similar to vitiligo, the eruption ...

Cutaneous adverse events (AEs) of anti-programmed cell death (PD ...

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.